Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design.

More information Original publication

DOI

https://doi.org/10.1016/S1473-3099(20)30914-2

Type

Alumni publications

Publisher

The Lancet

Publication Date

25/01/2021

Volume

21

Keywords

tuberculosis, therapy,